AMRI Acquired by The Carlyle Group and GTCR

Sep 06, 2017
By Pharmaceutical Technology Editors

On Aug. 31, 2017, the previously announced acquisition of AMRI was completed by affiliates of investment firms The Carlyle Group and Golder, Thomas, Cressey, Rauner (GTCR) for $21.75 per share in cash. AMRI president and CEO William S. Marth will continue leading the company.

Initially announced in June 2017, the agreement was unanimously approved by the AMRI board of directors, which had recommended that shareholders vote in favor of the transaction.

AMRI is a contract research and manufacturing organization with 25 years of experience in the pharmaceutical and biopharmaceutical industries. The company specializes in combining science and technology from start to finish of the drug discovery and development process. Its services include discovery, development, analytical and solid state services, and API manufacturing and drug product solutions.

Source: AMRI

native1_300x100
lorem ipsum